202 ES - Disease & Pharmacology Flashcards
Drugs used in pituitary disorder
Gonadotropin-releasing hormone (GnRH) analogues - Buserelin
Somatostatin analogues - Octreotide
Prolactin inhibitors - Bromocriptine
Growth hormone
Adenocorticoptropic hormone (ACTH) - Corticotropin
Vasopressin and analogues - Desmopressin
Gonadotropin-releasing hormone (GnRH) analogues
pituitary disorder
Buserelin
- stimulate FSH & LH
Somatostatin analogues
pituitary disorder
Octreotide
Lanreotide
Pariteotide
- inhibit pathologically increased secretion of GH
Treatments for acromegaly
Radiation therapy
Somatostatin analogue
- if not work → pituitary-directed medical therapy - Pegvisomant
Acromegaly
Excess GH
Prolactin inhibitors
pituitary disorder
Bromocriptine
Cabergoline
Qionagolide
- inhibit secretion of prolactin
Adrenocorticotropic hormone (ACTH) (pituitary disorder)
Corticotropin
- abandoned
Vasopressin and analogues
pituitary disorder
Desmopressin
Vasopressin
Terliopressin
- sm vasoconstriction
Drugs used in thyroid & parathyroid disorders
Thyroid Hormone Replacements - Levothyroxine (synthetic T4), Liothyronine (T3)
Thyroid Hormone Suppression - Thioamides - Carbimazole
Thyroid Hormone Replacements
thyroid & parathyroid disorders
Levothyroxine (synthetic T4)
Liothyronine (T3)
- converted to T3 which enters the nucleus and binds to a thyroid hormone receptor.
Thyroid Hormone Suppression
thyroid & parathyroid disorders
Thioamides:
- Carbimazole
- Methimazole
- Propylthiouracil
- Reduces the synthesis of thyroid hormones by inhibiting thyroperoxidase
Can radioactive iodine be used in pregnancy?
RAI is contraindicated in pregnancy & breastfeeding
Drugs for bone metabolism disorders
Antiresorptive drugs - Bisphosphonates, SERMs, Calcitonin, mAb
Anabolic Agents - Recombinant form of parathyroid hormone - teriparatide
Vitamin D Preparations - Ergocalciferol
Bisphosphonates
bone metabolism disorders
Alendronate
- anchor to cell surface proteins on osteoclast membrane by prenylation
Selective estrogen receptor modulators (SERMs)
bone metabolism disorders
Raloxifene
- inhibits cytokines that recruit osteoclasts
Calcitonin
bone metabolism disorders
Lowers blood calcium by:
Inhibits bone resorption by binding to a specific receptor on osteoclasts, inhibiting their action
Denosumab
bone metabolism disorders
Antiresorptive - mAb
IgG2 that inhibits RANKL - primary signal for bone resorption
Recombinant form of parathyroid hormone
bone metabolism disorders
Teriparatide
- Stimulation of new bone formation by direct effects on osteoblasts
Vitamin D preparations
bone metabolism disorders
Ergocalciferol
Alfacalcidol
Calcitriol
- act on receptors belonging to the steroid superfamily of receptors to increase serum calcium
Drugs used in adrenal disorders
Mineralocorticoid agonists (for Addison’s disease) & antagonists - fludrocortisone
Adrenal Hormone Replacement - Glucocorticoids
Adrenal Hormone suppression (Cushing’s syndrome) - adrenolytic agents, adrenal steroid inhibitors, glucocorticoid receptor (& progesterone receptor) antagonist
Fludrocortisone
adrenal disorders
Mineralocorticoid agonists
MOA: Mineralocorticoids interact with intracellular receptors in the kidney controlling transcription of specific genes that cause: ↑ number of Na+ channels, ↑ number of Na+ pumps.
Spironolactone
adrenal disorders
Mineralocorticoid antagonists
MOA: Competitive antagonist of aldosterone
Glucocorticoid
adrenal disorders
interact with intracellular receptors to inhibit the transcription of specific genes that code for various cytokines esp. IL-2.
Adrenal hormone replacement therapy (2)
Glucocorticoid Replacement therapy - hydrocortisone
Mineralocorticoid replacement therapy - fludrocortisone
Surgical intervention of Cushing’s syndrome
Transsphenoidal Selective Adenomectomy
Adrenalectomy - unilateral & total bilateral
Adrenolytic agents
adrenal disorders
Mitotane
- inhibits 11-beta hydroxylase & cholesterol side-chain cleavage enzymes
Adrenal steroid inhibitors
adrenal disorders
Metyrapone
Ketoconazole
Etomidate
Aminoglutethimide
Glucocorticoid receptor (& progesterone receptor) antagonist (adrenal disorders)
Mifepristone
- completely binds to glucocorticoid & progesterone receptors at high doses
What are neuroendocrine tumors (NETs)?
Rare tumors that occur in neuroendocrine cells in various organs
Can be malignant or benign
Functioning vs. non-functioning NETs
Functioning - secretes biogenic amines or hormones
Secretory but non-functioning - secretes peptides but cause no clinical symptoms
Non-functioning - non-secretory
Carcinoid syndrome
Develops when carcinoid tumor metastasize to liver & liver function is compromised
Types of NETs
GIT - 50%
- stomach
- small & large intestines
- pancreas
Lungs - 20%
Others
- skin
- prostate
- uterus
Most common origin of carcinoid tumors
Small & large intestines
Carcinoid tumor causes: ↑ histamine ↑ bradykinin
Which leads to?
Symptoms of carcinoid syndrome:
→ Vasodilation
Symptom: flushing itching
Carcinoid tumor causes: ↑ serotonin
Which leads to? (3)
Symptoms of carcinoid syndrome:
→ Fibrosis
Symptom: Pulmonary stenosis, tricuspid regurgitation
→ Bronchoconstriction
Symptom: Asthma, shortness of breath, wheezing
→ ↓ tryptophan → ↓ niacin (Vitamin B3)
Symptoms: Pellagra
Complications of carcinoid syndrome
Carcinoid heart disease
Carcinoid crisis
Bowel obstruction
Carcinoid heart disease
Thickening of heart valves may lead to leaking
Carcinoid crisis
Causes severe episodes of flushing, low bp, confusion & breathing difficulty
Bowel obstruction
Cancer that spreads to lymph nodes next to small intestine may cause narrowing & kinking of intestine
How to screen for carcinoid tumors?
Octreoscan
- Carcinoid tumors express more somatostatin receptors
Octreoscan can be used to image tumors that express an increased amount of somatostatin receptors
Pancreas NET arise from ______ cells.
Endocrine
Types of functional PanNETs
Insulinoma Gastrinoma VIPoma Glucagonoma Somatostatinoma
What is the most common type of PanNETs?
Insulinoma
- arise from β cells
- secrete insulin
- usually benign
- can cause hypoglycemia
Treatment of PanNETs
- functional
Functional:
- stomatostatin analogues to ↓ hormone production (exception: somatostatinomas) - Octreotide
- gastrinoma - PPI to block acid secretion - Omeprazole
Treatment of PanNETs
- non-functional
Large tumors can be managed by surgical removal
Somatostatin analogue (neuroendocrine tumor & treatment)
Octreotide
- slows down or stops production of hormones
When are targeted cancer drugs given?
When NET has become metastatic & cannot be removed by surgery.
Sunitinib
neuroendocrine tumor & treatment
For advanced kidney cancer, GI stromal tumor & panNETs
Everolimus
neuroendocrine tumor & treatment
Advanced breast cancer, NET of stomach, bowel, lung or pancreas, & kidney cancer
First-line treatment for NETs
Somatostatin analogue
What is a carcinoid tumor?
Tumour that secretes chemical into circulation, common in GI tract & lungs.
Type 1 diabetes
Due to cellular-mediated autoimmune destruction of pancreatic β cells
Type 2 diabetes
Relative insulin deficiency & peripheral insulin resistance
Maturity-Onset Diabetes of the Young (MODY)
Impaired insulin secretion w minimal or no defects in insulin action
Autosomal dominant
年青人成年型糖尿病
Neonatal diabetes
< 6 months of age
Can be transient or permanent
Autosomal dominant
Latent autoimmune diabetes in adults (LADA)
Adult onset autoimmune diabetes who were insulin independent for an extended time post-diagnosis
潛伏性成人自體免疫糖尿病
Type 1.5 diabetes
Clinical diagnosis of type 2 diabetes who test positive for autoantibodies
Gestational DM
Women who have DM during pregnancy
Insulin resistance symptoms
Altered fibrinolysis, Inflammation, Endothelial dysfunction Hyperinsulinemia Hypertension Hyperglycemia Dyslipidemia
Insulin resistance risks
Aging
Obesity
Sedentary lifestyle
Genetics
Metabolic syndrome (syndrome X)
Insulin resistance & abnormal adipose deposition/function
Diabetic ketoacidosis (DKA)
Characterized by hyperglycemia, ketoacidosis, ketonuria
- insulin deficiency inhibits ability of glucose to enter cells for utilization as metabolic fuel - liver rapidly breaks down fat into ketones to employ as fuel source
Diabetic ketoacidosis (DKA) is common with pt with ______.
Type I Diabetes
Hyperosmolar hyperglycemic state (HHS)
Commonly seen in pt with Type 2 diabetes, who have concomitant illness that leads to reduced fluid intake
Steps in managing type 2 diabetes
- Glucose control - improve glycemic control
- Reduce cardiovascular risk - controlling lipids & bp
- Manage comorbidities
Diabetic dyslipidemia symptoms & treatment
Symptoms:
↑ triglycerides
↓ HDL cholesterol
Small dense LDL particles
Treatment:
Treat w statin initially
Hypertension (w diabetes) is treated w?
Renin-angiotensin-aldosterone system inhibitors (RAASi)
Insulin & insulin analogue - rapid-acting
insulin analogs
Insulin lispro
Insulin aspart
Insuline glulisine
Thyroid eye disease
Autoimmune disease characterized by progressive inflammation & damage to tissues around the eyes, especially extraocular muscle, connective, and fatty tissue
Which gender is more likely to have thyroid eye disease?
Women
Sulfonylureas
treatment for diabetes
1st gen: Tolbutamide
2nd gen: Gibenclamide
Interact with the sulfonylurea receptor on surface of pancreatic b cells
Meglitinides
treatment for diabetes
Repaglinide
Same action as sulfonylurea - interact w receptor on surface of pancreatic b cells
Biguanides
treatment for diabetes
Metformin
Reduce hepatic glucose production through activation of AMP-activated protein kinase (AMPK)
1st line in T2DM
Alpha-glucosidase inhibitors
treatment for diabetes
Acarbose
- Inhibits intestinal α-glucosidase and pancreatic α-amylase so reduces the rise in blood glucose which follows a meal
Thiazolidinediones
treatment for diabetes
Pioglitazone
- ligands of peroxisome targeting the PPAR-γ receptor
DPP-4 inhibitors
treatment for diabetes
Sitagliptin
Competitively inhibit DPP-4, thereby lowering blood glucose by potentiating endogenous incretins (GLP-1 and GIP) which stimulate insulin secretion.
GLP-1 Receptor Agonists
treatment for diabetes
Liraglutide
- inhibits pancreatic glucagon secretion & ↑ insulin
SGLT2 inhibitors
treatment for diabetes
Dapagliflozin
- Act by promoting glucose excretion into the urine, thereby reducing the concentration of circulating glucose.
Adverse effect of Sulfonylureas & Meglitinides
treatment for diabetes
Hypoglycemia
Drugs for treatments of diabetes
Insulin Sulfonylureas - Gibenclamide Meglitinides - Repaglinide Metformin Alpha-glucosidase inhibitors - Acarbose Thiazolidinediones - Pioglitazone DPP-4 inhibitors - Sitagliptin GLP-1 Receptor Agonists - Exenatide SGLT-2 inhibitors - Canagliflozin
Main form of energy storage
Fat in adipose tissue
What hormones are orexigenic (stimulate feeding)?
Ghrelin
Neuropeptide Y
Orexin A & B
What hormones are anorexigenic (signal satiety)?
Leptin Insulin Glucagon Melanocortins (product of POMC) Cholecystokinin Glucagon-like peptide 1
Main action of leptin
Reduces appetite & ↓ food consumption
Leptin:
Over-feeding ______ concentration; Starvation ______ concentration
increases; decreases
Leptin effects on energy store
- energy intake > energy expenditure
Adipose tissue - ↑ fat deposition, ↑ leptin secretion
→ hypothalamus - altered activity of integrating centers → ↓ energy intake, ↑ metabolic rate
Leptin effects on energy store
- energy intake < energy expenditure
Adipose tissue - ↓ fat deposition, ↓ leptin secretion
→ hypothalamus - altered activity of integrating centers → ↑ energy intake, ↓ metabolic rate
What receptor does leptin bind?
ObR
Leptin binds to POMC expressing ObR results in?
↓ food intake
Leptin binds to NPY expressing ObR results in?
Inhibiting NPY actions in ↑ food intake
∴ ↓ food intake
Effects of neuropeptide Y
Stimulates food intake
↓ latency to eat
↑ motivation to eat
Delays satiety (increases meal size)
NPY secretion is upregulated when?
Food deprivation/restriction
Lack of leptin
Effect of POMC
↓ food intake & ↑ energy expenditure
How does POMC suppress appetite?
By releasing α-melanocyte stimulating hormone (α-MSH).
Leptin ______ BMR.
increases
Leptin resistance
Diminished response to anorexigenic effects of leptin
Actions of ghrelin
Appetite stimulator, regulated by feeding status
Stimulates NPY
Stimulates GH release
Control of ghrelin secretion
Fasting/low-calorie diet → ↑ ghrelin secretion in stomach → ↑ hunger → ↑ food intake → stomach distention or caloric absorption → ↓ ghrelin secretion
How does orexin work with ghrelin to stimulate appetite?
Orexin production is activated by ghrelin and inhibited by leptin.
Regulates arousal, wakefulness and appetite
Ventral-medial hypothalamic NPY neurons ______ feeding
stimulate
Lateral hypothalamic POMC neurons ______ satiety
stimulate
What’s the only approved orexigenic drug for treatment of AIDS-induced anorexia?
Dronabinol
Approved anorexigenic drugs (appetite-suppressing)
Orlistat
Liraglutide
Lorcaserin
BMI (kg/m2) = ?
weight (kg)/ height^2 (m^2)
What BMI is considered as obesity in Asian & white European populations?
Asian: ≥27.5
White European: ≥30
Drugs to treat obesity
Orlistat
- inhibition of lipases blocks absorption of dietary fat
Treatment for Addison’s disease
Mineralcorticoid agonist - fludrocortisone
Treatment for Cushing’s syndrome
Adrenal Hormone Suppression
Adrenolytic agents - Mitotane
Adrenal steroid inhibitors - Metyrapone
Glucocorticoid receptor (& progesterone receptor) - Mifepristone
Abiraterone
Insulin & insulin analogue - intermediate-acting & long-acting
(insulin analogs)
NPH/isophane insulin
Insulin glargine
Insulin detemir